Processa Pharmaceuticals, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Processa Pharmaceuticals, Inc. (PCSA) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$306.57 thousand for the 3-month period ending 2015-09-30, per its 10-Q filed 2015-12-01.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2015-12-01
- Processa Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2015-09-30 was -$306.57K.
- Processa Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2015-06-30 was -$2.06M.
- Processa Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2015-03-31 was -$655.20K.
- Processa Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2014-12-31 was -$2.90M.
- Processa Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for fiscal 2014 was -$6.03M.
- Processa Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for fiscal 2013 was -$3.09M.
- Processa Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for fiscal 2012 was -$2.77M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month | Net Income (Loss) Available to Common Stockholders, Diluted 33 month | Net Income (Loss) Available to Common Stockholders, Diluted 36 month |
|---|---|---|---|---|---|---|
| 2015-09-30 | -$306.57K 10-Q · filed 2015-12-01 | -$2.37M derived: sum of 2 quarters · filed 2015-12-01 | -$3.02M 10-Q · filed 2015-12-01 | -$5.93M derived: sum of 4 quarters · filed 2015-12-01 | ||
| 2015-06-30 | -$2.06M 10-Q · filed 2015-08-19 | -$2.72M 10-Q · filed 2015-08-19 | -$5.62M derived: sum of 3 quarters · filed 2015-08-19 | -$6.49M derived: sum of 4 quarters · filed 2015-12-01 | ||
| 2015-03-31 | -$655.20K 10-Q · filed 2015-05-15 | -$3.56M derived: sum of 2 quarters · filed 2015-05-15 | -$4.43M derived: sum of 3 quarters · filed 2015-12-01 | -$5.34M derived: sum of 4 quarters · filed 2015-12-01 | ||
| 2014-12-31 | -$2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2015-04-14 | -$3.77M derived: sum of 2 quarters · filed 2015-12-01 | -$4.69M derived: sum of 3 quarters · filed 2015-12-01 | -$6.03M 10-K · filed 2015-04-14 | ||
| 2014-09-30 | -$871.84K 10-Q · filed 2015-12-01 | -$1.78M derived: sum of 2 quarters · filed 2015-12-01 | -$3.13M 10-Q · filed 2015-12-01 | -$3.76M derived: sum of 4 quarters · filed 2015-12-01 | ||
| 2014-06-30 | -$912.35K 10-Q · filed 2015-08-19 | -$2.25M 10-Q · filed 2015-08-19 | -$2.88M derived: sum of 3 quarters · filed 2015-08-19 | -$3.82M derived: sum of 4 quarters · filed 2015-08-19 | ||
| 2014-03-31 | -$1.38M 10-Q · filed 2015-05-15 | -$1.97M derived: sum of 2 quarters · filed 2015-05-15 | -$2.91M derived: sum of 3 quarters · filed 2015-05-15 | -$3.67M derived: sum of 4 quarters · filed 2015-05-15 | -$8.26M 10-Q · filed 2014-05-14 | |
| 2013-12-31 | -$589.63K derived: 10-K 12 month − 10-Q 9 month · filed 2015-04-14 | -$1.52M derived: sum of 2 quarters · filed 2015-04-14 | -$2.29M derived: sum of 3 quarters · filed 2015-04-14 | -$3.09M 10-K · filed 2015-04-14 | -$6.88M 10-K · filed 2014-03-27 | |
| 2013-09-30 | -$932.60K 10-Q · filed 2014-11-13 | -$1.70M derived: sum of 2 quarters · filed 2014-11-13 | -$2.50M 10-Q · filed 2014-11-13 | |||
| 2013-06-30 | -$768.36K 10-Q · filed 2014-08-19 | -$1.63M 10-Q · filed 2014-08-19 | ||||
| 2013-03-31 | -$915.31K 10-Q · filed 2014-05-14 | |||||
| 2012-12-31 | -$2.77M 10-K · filed 2014-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |